JP2024511676A - 術後回復のためのオレキシン２受容体アゴニストの使用 - Google Patents
術後回復のためのオレキシン２受容体アゴニストの使用 Download PDFInfo
- Publication number
- JP2024511676A JP2024511676A JP2023560767A JP2023560767A JP2024511676A JP 2024511676 A JP2024511676 A JP 2024511676A JP 2023560767 A JP2023560767 A JP 2023560767A JP 2023560767 A JP2023560767 A JP 2023560767A JP 2024511676 A JP2024511676 A JP 2024511676A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- subject
- opioid
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170211P | 2021-04-02 | 2021-04-02 | |
| US63/170,211 | 2021-04-02 | ||
| PCT/IB2022/053085 WO2022208478A1 (en) | 2021-04-02 | 2022-04-01 | Use of an orexin 2 receptor agonist for post operation recovery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511676A true JP2024511676A (ja) | 2024-03-14 |
| JP2024511676A5 JP2024511676A5 (https=) | 2025-04-15 |
Family
ID=81326367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560767A Pending JP2024511676A (ja) | 2021-04-02 | 2022-04-01 | 術後回復のためのオレキシン２受容体アゴニストの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240165092A1 (https=) |
| EP (1) | EP4313045A1 (https=) |
| JP (1) | JP2024511676A (https=) |
| KR (1) | KR20230165782A (https=) |
| CN (1) | CN117396203A (https=) |
| AU (1) | AU2022252108A1 (https=) |
| BR (1) | BR112023020104A2 (https=) |
| CA (1) | CA3215906A1 (https=) |
| CO (1) | CO2023013001A2 (https=) |
| MX (1) | MX2023011669A (https=) |
| TW (1) | TW202304437A (https=) |
| WO (1) | WO2022208478A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202502342A (zh) * | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7413261B2 (ja) | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| CA3154321A1 (en) * | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2022
- 2022-04-01 BR BR112023020104A patent/BR112023020104A2/pt unknown
- 2022-04-01 CN CN202280037124.XA patent/CN117396203A/zh active Pending
- 2022-04-01 US US18/553,348 patent/US20240165092A1/en active Pending
- 2022-04-01 CA CA3215906A patent/CA3215906A1/en active Pending
- 2022-04-01 TW TW111112864A patent/TW202304437A/zh unknown
- 2022-04-01 AU AU2022252108A patent/AU2022252108A1/en active Pending
- 2022-04-01 WO PCT/IB2022/053085 patent/WO2022208478A1/en not_active Ceased
- 2022-04-01 EP EP22715747.6A patent/EP4313045A1/en active Pending
- 2022-04-01 KR KR1020237033928A patent/KR20230165782A/ko active Pending
- 2022-04-01 MX MX2023011669A patent/MX2023011669A/es unknown
- 2022-04-01 JP JP2023560767A patent/JP2024511676A/ja active Pending
-
2023
- 2023-09-29 CO CONC2023/0013001A patent/CO2023013001A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022208478A1 (en) | 2022-10-06 |
| KR20230165782A (ko) | 2023-12-05 |
| CO2023013001A2 (es) | 2023-10-30 |
| CN117396203A (zh) | 2024-01-12 |
| US20240165092A1 (en) | 2024-05-23 |
| CA3215906A1 (en) | 2022-10-06 |
| AU2022252108A1 (en) | 2023-10-05 |
| BR112023020104A2 (pt) | 2023-11-14 |
| MX2023011669A (es) | 2023-10-18 |
| TW202304437A (zh) | 2023-02-01 |
| EP4313045A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6931019B2 (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP5907975B2 (ja) | 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ | |
| JP2003529563A (ja) | ビュープロピオン代謝産物並びにその合成および使用方法 | |
| WO2012166909A1 (en) | Compositions and methods for treating breathing control disorders or diseases | |
| RU2011146032A (ru) | Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности | |
| JP2025084754A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| TW200831097A (en) | Treatment of anxiety with eszopiclone | |
| TW201607539A (zh) | 加巴噴丁類似物和σ受體配體組合物 | |
| US20220096444A1 (en) | Prophylactic or therapeutic agent for delirium | |
| US20210145785A1 (en) | Compositions and methods for stimulating ventilatory and/or respiratory | |
| JP2024511676A (ja) | 術後回復のためのオレキシン２受容体アゴニストの使用 | |
| JP5042625B2 (ja) | 抗炎症剤として有用なα−アミノアミド誘導体 | |
| JP2025506252A (ja) | 鎮痛及び／又は鎮痒機能を有する医薬組成物及びその使用 | |
| WO2022004788A1 (ja) | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 | |
| JP2023520455A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| CN111670041A (zh) | 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合 | |
| JPH09500375A (ja) | パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用 | |
| US20250262181A1 (en) | Compositions and methods for stimulating ventilatory and/or respiratory | |
| EA017090B1 (ru) | Комбинация модафинила и 1-{3-[3-(4-хлорфенил)пропокси]пропил}пиперидина | |
| WO2022190060A1 (en) | An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder | |
| JP6216913B1 (ja) | 医薬組成物 | |
| EP4719397A1 (en) | Use of an orexin 2 receptor agonist for improving respiratory function during sleep | |
| TW202508584A (zh) | 癌性疼痛預防或治療用組成物 | |
| JP2025527796A (ja) | 睡眠時無呼吸を治療するための方法及び組成物 | |
| CA3210092A1 (en) | Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250331 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250331 |